25 results on '"Vlad, Catalin"'
Search Results
2. Decrease of oncological patients' hospital visits during Covid-19 pandemic; the experience of a tertiary Romanian centre.
- Author
-
Crisan C, Cainap C, Deac A, Havasi A, Balacescu O, Balacescu L, Bochis O, Vlad C, and Cainap S
- Subjects
- COVID-19 epidemiology, COVID-19 transmission, COVID-19 virology, Delivery of Health Care, Integrated, Humans, Neoplasms virology, Romania epidemiology, SARS-CoV-2 isolation & purification, Tertiary Care Centers, COVID-19 complications, Hospitalization statistics & numerical data, Hospitals statistics & numerical data, Inpatients statistics & numerical data, Neoplasms therapy, Outpatients statistics & numerical data, Patient Acceptance of Health Care statistics & numerical data
- Abstract
Purpose: The outbreak of COVID-19 pandemic has changed the provision of medical services worldwide. We assessed the impact of the pandemic on the oncological patients' visits to a tertiary cancer centre., Methods: We analysed registrations from the administrative data system of in- and outpatients in all of the departments of the Cluj-Napoca Oncology Institute, during March-October 2020, and compared to the same 7-month period of the previous year., Results: The decrease during March-October 2020 was 40.2% for new referrals overall (with the most significant drop in April, of 80%), 52.5% for medical oncology inpatients, 39% for paediatric oncology department inpatients, 69% for radiotherapy inpatients, 34.9% for surgical interventions and 31% decrease of issued pathology reports. The decrease was less important for outpatients: only 10% for medical oncology outpatient department, 33% for radiotherapy and 27% for breast cancer unit outpatients. Imaging investigations were only slightly influenced by the pandemic (reduction of 5% for MRI scans, 19% for mammograms,whereas performed CT scans were even more after the outbreak of COVID-19)., Conclusion: Our results show a decrease in the number of patients during the period after the outbreak of the COVID-19 pandemic, more for inpatients and less significant for outpatient departments, probably because of the internal circuits reorganization but also because of health care measures taken nationally and locally to limit the spread of the pandemic.
- Published
- 2021
3. Indocyanine green use in Urology.
- Author
-
Petrut B, Bujoreanu CE, Porav Hodade D, Hardo VV, Ovidiu Coste B, Maghiar TT, Achimas Cadariu P, and Vlad C
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Indocyanine Green chemistry, Urology methods
- Abstract
Purpose: Indocyanine green (ICG) is being used more and more in Urology along with advances in minimal invasive surgery, guiding excision and reconstruction, highlighting anatomic structures and functional features with oncologic guidance still being debatable. The purpose of this paper was to explore ICG use in urologic procedures., Methods: We present our experience (37 cases) of using ICG fluorescence guidance in urologic operations performed using 3D laparoscopy and FireFly® fluorescence imaging mode of Da Vinci X robot. The operations were the following: pelvic lymphadenectomy in radical prostatectomy, totally intracorporeal orthotopic ileal neobladder reconstruction, vesicovaginal fistula repair, partial nephrectomy and pyeloplasty. Barnard's test was used to compare postoperative complications (digestive fistula, ureteral stricture) for totally intracorporeal ileal neobladders performed with (group e, 27 cases) vs. without (group 2, 28 cases) ICG guidance., Results: ICG under near-infrared fluorescence offered a precise identification of ischemic structures- vaginal wall, distal ureteral end, ileal loop, along with vascularized tissues allowing an optimal pyeloplasty and nephron sparing surgery with partial unclamping. It also allowed the identification of a lymph node during radical prostatectomy that otherwise would not have been excised during the routinely performed pelvic lymphadenectomy. There were no complications of ICG usage and the complication rate (digestive fistula, ureteral strictures) was significantly lower (p=0.002716) for group 1 compared with group 2., Conclusions: ICG facilitates the identification of key elements (anatomy and pathological structures) in the laparoscopic and robotic treatment of both malignant and benign urologic diseases, with possible impact on perioperative complications, along with oncologic and functional postoperative outcomes.
- Published
- 2021
4. Institutional results of OncoOVARIAN Dx - a novel algorithm for the preoperative evaluation of adnexal masses.
- Author
-
Kubelac P, Craciun A, Jalba O, Gheorghe S, Lazar G, Ignat F, Lisencu C, Rancea A, Vlad C, Irimie A, and Achimas Cadariu P
- Subjects
- Algorithms, Biomarkers, Tumor metabolism, Carcinoma, Ovarian Epithelial metabolism, Female, Humans, Menopause metabolism, Middle Aged, Sensitivity and Specificity, Carcinoma, Ovarian Epithelial pathology, Neoplasms, Adnexal and Skin Appendage metabolism, Neoplasms, Adnexal and Skin Appendage pathology
- Abstract
Purpose: The purpose of this study was to evaluate the predictive performance of OncoOVARIAN Dx algorithm, which takes into account tumor markers (beta HCG, CA 19.9, CEA, AFP, CA 125, HE4), general biochemistry and clinical data (age, menopause, comorbidities) in patients scheduled for surgical removal of a suspicious adnexal tumor in comparison with the Risk of Malignancy Algorithm (ROMA) model., Methods: Consecutive women diagnosed with an adnexal tumor mass and scheduled for surgical intervention at a single tertiary cancer between October 2018 - June 2019 were enrolled. Preoperative values of tumor markers and general biochemistry (ASAT, ALAT, GGT, total bilirubin, creatinine) were determined. Following surgery with adequate surgical staging, a definite pathological diagnosis was made and used as reference., Results: A total of 50 patients were selected, including 20 benign, 5 borderline and 25 malignant epithelial ovarian cancer (EOC) cases on final pathology. Borderline tumors comprised 3 serous and 2 mucinous FIGO stage I cases. Malignant tumors included 17 high grade serous, 4 endometrioid and 4 mucinous types, FIGO stage IA-IIIC. The two models demonstrated very good correlation (Phi 0.78, p<0.001). The sensibility (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV) of OncoOVARIAN Dx versus ROMA model were 76.66% vs. 60%, 95% vs. 100%, 95.83% vs. 100%, 73.07% vs. 62.5%, respectively. In postmenopausal patients higher Se (85.71%), Sp (100%) and PPV (100%) were observed for OncoOVARIAN Dx., Conclusions: OncoOVARIAN Dx model demonstrated higher Se and NPV compared to ROMA and could be a useful marker in the preoperative management of adnexal masses; however larger studies are warranted to validate and further refine this algorithm.
- Published
- 2020
5. Is there a place for F18-FDG PET/CT in the diagnosis of primary breast cancer?
- Author
-
Stefan Morariu D, Vlad C, Puscas ME, Gata V, and Piciu D
- Subjects
- Female, Humans, Breast Neoplasms diagnostic imaging, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography methods
- Abstract
Purpose: With the improvement of techniques and the update of diagnostic protocols in breast cancer, modern imaging proves to be effective in the diagnosis of this pathology, as well as in its prognosis. This study aimed to evaluate the effectiveness of these modern imaging techniques through a systematic assessment of the most recent studies., Methods: A PUBMED search, using certain key combinations ("breast cancer", "F18 FDG PET-CT", "MRI", "staging", "diagnosis") and some inclusion and exclusion criteria, yielded 24 articles published during 2014-2018., Results: Using these 24 articles, the various statistical tests showed a significant difference between modern imaging techniques, with respect to prognosis (p<0.05), in close correlation with the immunohistochemical profile of the tumor., Conclusions: Modern imaging techniques (F18-FDG/PET-CT, F18-FDG/PET-MRI) were validated to formulate a better prognostic value than conventional imaging, presenting a sustainable higher sensitivity and specificity in evidencing the locoregional invasion and the recurrence of this pathology.
- Published
- 2020
6. Totally intracorporeal 3D laparoscopic orthotopic neobladder reconstruction following radical cystectomy for infiltrative bladder tumors: the experience of modified Studer and modified Y-shaped ileal reconstruction techniques.
- Author
-
Bogdan Rusu C, Bujoreanu CE, Irimie A, Achimas-Cadariu P, Vlad C, Kubelac P, Hardo VV, Maghiar TT, Maris CV, Idris Y, and Petrut B
- Subjects
- Female, Humans, Male, Urinary Bladder Neoplasms pathology, Cystectomy methods, Ileum surgery, Imaging, Three-Dimensional methods, Laparoscopy methods, Plastic Surgery Procedures methods, Urinary Bladder Neoplasms surgery
- Abstract
Purpose: We report our experience with 23 cases in utilizing ileum to perform totally intracorporeal 3D laparoscopic neobladder reconstruction using two different surgical techniques., Methods: Patients candidates for reconstructive surgery were in a good biological status with a body mass index (BMI) in the range of 18.5-25 and presented a muscle-infiltrative bladder tumor with negative nodal frozen sections performed during the operation. Twenty-one modified Studer neobladder and 2 modified Y-shaped neobladder techniques for totally intracorporeal 3D laparoscopic ileal neobladder cases were performed using drawings and intra-operative images. An emphasis was made on different tips and tricks that can be applied when using ileum for the neobladder reconstruction, to avoid surgical complications and obtain optimal functional results., Results: The operations were performed in a mean time of 5 h, with a mean blood loss of 350 ml and grade II postoperative Clavien Dindo complications. The 23 patients were discharged after a mean hospital stay of 21 days and had a functional ileal neobladder after a mean of 30 days. The results were monitored also on the long-term, taking into account functional results and possible complications from utilizing ileum as a urinary reservoir., Conclusion: Resecting a digestive segment and using it as a urinary reservoir may lead to multiple complications. Therefore, laparoscopic technical adaptations and highly skilled surgical teams are required for performing a totally intracorporeal 3D laparoscopic orthotopic ileal neobladder reconstruction.
- Published
- 2020
7. Exosomal miRNAs in colorectal cancer: the carriers of useful news.
- Author
-
Sur D, Coza O, Havasi A, Cainap C, Burz C, Vlad C, Balacescu O, Alexandru I, and Lisencu C
- Subjects
- Humans, Prognosis, Biomarkers, Tumor metabolism, Colorectal Neoplasms diet therapy, Colorectal Neoplasms genetics, Exosomes metabolism, MicroRNAs metabolism
- Abstract
Purpose: In this review, we focused on presenting an up-to-date overview of exosomal miRNAs as biomarkers for diagnosis, prognosis, and their therapeutically perspectives in colorectal cancer (CRC)., Methods: A comprehensive literature search was conducted using the PUBMED database through February 2019 to identify all studies concerning the role of miRNAs and exosomes in CRC., Results: Among the 77 studies identified, 43 articles were relevant for the collaboration of miRNAs and exosomes as therapeutic and diagnostic opportunities in CRC., Conclusions: This review reveals the role of exosomal miRNAs in CRC management and discusses the promises and challenges associated with the introduction of this combination into clinical practice.
- Published
- 2020
8. Gastric cancer: adjuvant chemotherapy versus chemoradiation. A clinical point of view.
- Author
-
Cainap C, Vlad C, Seicean A, Balacescu O, Seicean R, Constantin AM, Balacescu L, Crisan O, Marta MM, and Cainap S
- Subjects
- Humans, Prognosis, Stomach Neoplasms pathology, Chemoradiotherapy methods, Chemotherapy, Adjuvant methods, Stomach Neoplasms drug therapy, Stomach Neoplasms radiotherapy
- Abstract
Gastric cancer represents one of the most severe cancers with poor overall survival. Despite the availability of published data on the efficacy of adjuvant treatment, the actual percentage of treated patients remains low. The toxicity of radiotherapy or chemotherapy regimens differ and clinicians need accessible tools in order to better select candidates for adjuvant treatment. In this review, we present published data from clinical trials and cancer registries that might be useful for properly balancing the efficacy and toxicity of adjuvant treatment in gastric cancer patients who underwent surgery with curative intent.
- Published
- 2019
9. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
- Author
-
Sur D, Cainap C, Burz C, Havasi A, Chis IC, Vlad C, Milosevic V, Balacescu O, and Irimie A
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Cetuximab adverse effects, Clinical Decision-Making, Colorectal Neoplasms genetics, Colorectal Neoplasms metabolism, Colorectal Neoplasms pathology, ErbB Receptors antagonists & inhibitors, ErbB Receptors metabolism, Gene Expression Regulation, Neoplastic, Humans, MicroRNAs metabolism, Molecular Targeted Therapy, Mutation, Neoplasm Metastasis, Panitumumab adverse effects, Patient Selection, Precision Medicine, Protein Kinase Inhibitors adverse effects, Signal Transduction, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cetuximab therapeutic use, Colorectal Neoplasms drug therapy, MicroRNAs genetics, Panitumumab therapeutic use, Protein Kinase Inhibitors therapeutic use, Proto-Oncogene Proteins p21(ras) genetics
- Abstract
Colorectal cancer (CRC) is one of the most common cancers worldwide with a high incidence and mortality. Although many treatment options are available in stage IV disease, the clinical outcome is still minimal. The primary treatment problem in metastatic colorectal cancer (mCRC) is early liver metastases that occur in more than 50% of patients. First-line treatment in metastatic colorectal cancer (mCRC) is a combination of chemotherapy plus targeted therapies like Cetuximab or Bevacizumab depending on K-RAS status. The decision of which regimen to choose is difficult because almost half of the patients don't receive second-line treatment due to complications or death. To avoid exposing non-responding patients to inefficient and harmful therapies new robust biomarkers are needed. Ongoing studies have demonstrated constantly that microRNAs (miRNAs) could become suitable biomarkers for screening and treatment response. In CRC, miR-31-3p and miR-31-5p dysregulation seems to have a particular role in evaluating treatment response from anti-EGFR therapy. In this review, we will present up to date information on the role of miRNA-31-3p and miR-31-5p in CRC with a particular focus in treatment response of metastatic K-RAS wild-type CRC treated with anti-EGFR molecules.
- Published
- 2019
10. The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.
- Author
-
Kubelac P, Vlad C, Berindan Neagoe I, Irimie A, and Achimas Cadariu P
- Subjects
- DNA Damage genetics, DNA Repair genetics, Disease-Free Survival, Female, Humans, Middle Aged, Mutation, Neoadjuvant Therapy adverse effects, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Ovarian Neoplasms pathology, Ovarian Neoplasms surgery, Platinum therapeutic use, Prognosis, BRCA1 Protein genetics, BRCA2 Protein genetics, Neoplasm Recurrence, Local genetics, Ovarian Neoplasms genetics
- Abstract
Purpose: The treatment of ovarian cancer continues to pose a challenge especially through the development of platinum-resistant disease and still has the highest mortality rate among gynecologic cancers. Patients are usually diagnosed with advanced stages where complete cytoreduction and standard platinum-based chemotherapy are the mainstay of treatment. Advances into the molecular underpinnings of DNA damage repair highlighted BRCA 1/2 and other related genes as key regulators of platinum sensitivity. Our study characterizes clinical features and outcomes associated with BRCA mutations in a cohort of ovarian cancer patients., Methods: Patient data from our Institute was retrospectively extracted for all patients that were tested for the presence of BRCA germline or somatic mutations through next generation sequencing between May 2016 and August 2018., Results: Eighty-eight patients were included in the present analysis. Advanced FIGO stage IIIC-IV was common at presentation (71.6%), with 58% of patients undergoing primary debulking surgery. BRCA mutant cases represented 44% and were associated with a significantly higher frequency for complete pathologic response, first and second platinum sensitive relapse and a significantly longer overall survival for advanced stage cases treated with neoadjuvant chemotherapy. Mean age at presentation was significantly lower in the BRCA mutated (52 years) compared to BRCA wildtype patients (54.2 years, p=0.045)., Conclusions: Upfront knowledge of BRCA status is encouraged, given the recent advent of targeted therapies and for the decision regarding optimal sequence of available therapeutic strategies.
- Published
- 2019
11. Clinical outcomes and cost-effectiveness of primary treatment of ovarian cancer in North-Western Romania.
- Author
-
Onisim A, Achimas Cadariu P, Iancu M, Puscas E, Bodog A, and Vlad C
- Subjects
- Adult, Aged, Cost-Benefit Analysis, Female, Humans, Middle Aged, Ovarian Neoplasms mortality, Romania, Survival Rate, Treatment Outcome, Ovarian Neoplasms economics, Ovarian Neoplasms therapy
- Abstract
Purpose: Ovarian cancer has the poorest survival rate among gynaecological malignancies. Besides the comparison of different therapeutic strategies aimed to improve outcomes, studies have also begun to focus on aspects of cost-effectiveness of these strategies. In this context, we proposed to evaluate the survival impact, costs and cost-effectiveness of two primary treatment options, primary debulking surgery (PDS) versus neoadjuvant chemotherapy (NACT), in patients with advanced ovarian cancer treated in a tertiary cancer center of the North-Western Romania., Methods: The study included patients with stages IIIC and IV ovarian cancer treated at the "Prof. Dr. Ion Chiricuta" Institute of Oncology, Cluj-Napoca, between 2008-2011, by either PDS or NACT. Survival was the measure of the effectiveness of the two treatments. A cost-effectiveness analysis was carried out by estimating the incremental cost-effectiveness ratio (ICER) and the average cost-effectiveness ratio (ACER)., Results: There was no significant difference in overall survival between the two treatment groups. The median costs for the NACT subgroup were 3580.41 € compared to 2990.19 € for the PDS subgroup, with an incremental cost of 590.22 €. The effectiveness measured in years of survival was 3.34 years for NACT and 3.57 years for PDS. The corresponding median ICER was -2566.17 €/year of survival. ACER was higher for NACT compared to PDS (1071.98 vs. 837.59 €/year of survival)., Conclusions: Despite the higher costs, NACT did not prove to be a more effective therapeutic strategy in terms of survival of patients with stage IIIC/IV ovarian cancer. Altogether, our results state that NACT might be less cost-effective than PDS.
- Published
- 2019
12. The role of CD146 in serous ovarian carcinoma.
- Author
-
Onisim A, Vlad C, Simon I, Dina C, and Achimas Cadariu P
- Subjects
- Adult, Aged, Cystadenocarcinoma, Serous blood supply, Female, Humans, Middle Aged, Neovascularization, Pathologic metabolism, Neovascularization, Pathologic pathology, Ovarian Neoplasms blood supply, Prognosis, CD146 Antigen biosynthesis, Cystadenocarcinoma, Serous metabolism, Ovarian Neoplasms metabolism
- Abstract
Purpose: The heterogeneous phenotype of epithelial ovarian cancer (EOC) explains the unpredictable behaviour in terms of response to therapy, time to progression and survival. In this context, CD146, a cell adhesion molecule, has been focused on as a marker of poor prognosis in various solid cancers, being also capable to modulate the activity of endothelial cells. Therefore, we proposed to investigate its role in serous ovarian carcinoma., Methods: The study included 101 patients diagnosed with EOC and treated within "Ion Chiricuta" Oncology Institute by optimal surgical debulking followed by platinum-based chemotherapy. Clinico-pathological characteristics were collected from patient files. CD146 expression was assessed by immunohistochemistry in serous ovarian carcinoma primary tumours, taking into account both staining intensity and the percentage of positive tumor cells. Expression of CD146 in endothelial cells of tumour microvessels was also evaluated. CD34 immunostaining was used for intratumoral microvessel density estimation., Results: CD146 positivity in tumor cells was objectified in 49.5% of samples and 37.1% presented a high CD146 endothelial expression. Our analysis showed that CD146 was as reliable as CD34 for microvascular density estimation. The distribution of cases according to CD146 tumor expression was similar regardless of age, initial serum CA125 level, FIGO stage, presence/absence of malignant ascites. Multivariate analysis confirmed that expression of CD146 in tumor cells was a negative prognostic factor for overall survival, significantly asociated with a higher risk of chemotherapy resistance., Conclusions: Although CD146 immunoreactivity in tumor cells did not correlate with the routinely used clinico-pathological parameters, expression of CD146 in tumor cells was an independent pronostic factor for survival in serous ovarian carcinomas. Moreover, CD146 might be regarded as a novel biomarker of tumor neovasculature.
- Published
- 2019
13. The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia.
- Author
-
Raluca Maniu D, Blag C, Popa G, Bota M, Vlad C, Cainap C, Balacescu O, Pop L, and Cainap SS
- Subjects
- Adolescent, Antibiotics, Antineoplastic adverse effects, Cardiotoxicity etiology, Cardiotoxicity metabolism, Cardiotoxicity pathology, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Infant, Leukemia, Myeloid, Acute pathology, Male, Natriuretic Peptide, Brain metabolism, Peptide Fragments metabolism, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Prognosis, Survival Rate, Troponin T metabolism, Anthracyclines adverse effects, Biomarkers metabolism, Cardiotoxicity diagnosis, Echocardiography methods, Leukemia, Myeloid, Acute drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Risk Assessment methods
- Abstract
Purpose: To describe the high-risk profile group, susceptible to develop anthracycline-induced cardiomyopathy in children with acute leukemia., Methods: The study involved 35 pediatric patients diagnosed with acute lymphoblastic (ALL) or acute myeloblastic leukemia (AML), from March 2014 to December 2016. Serologic markers used for the analysis of cardiac dysfunction were troponin T, NT-proBNP and PCRhs. Also, the patients have had echocardiographic evaluation at the beginning of treatment to determine LVEF, SF and A, E, E' Doppler waves., Results: Positive linear correlation was shown between NT-proBNP and leukocyte values, NT-proBNP and blast cells value, and NT-proBNP and LDH. Significant linear negative correlations between LVEF with leukocyte values, blast cells values, LDH, SF and leukocyte values, LVEF and NT-proBNP values and LVEF and troponin T values were also identified. A weak negative correlation between E/E' ratio and blast cells values has been observed. All of these correlations were statistically significant (p<0.05)., Conclusions: Leukocyte value, as well as the other serological markers assessed (NT-proBNP, Troponin T), are useful tools to evaluate the risk of anthracycline-induced cardiotoxicity. The variation of the biological markers at the beginning of the cytotoxic treatment confirms the presence of an early myocardial dysfunction, emphasizing the importance of systematic evaluation of this particular group of patients.
- Published
- 2018
14. Expression of toll-like receptors in ovarian cancer.
- Author
-
Vlad C, Dina C, Kubelac P, Vlad D, Pop B, and Achimas Cadariu P
- Subjects
- Cystadenocarcinoma, Serous drug therapy, Cystadenocarcinoma, Serous metabolism, Female, Follow-Up Studies, Humans, Middle Aged, Ovarian Neoplasms drug therapy, Ovarian Neoplasms metabolism, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms metabolism, Prognosis, Prospective Studies, Survival Rate, Tumor Microenvironment, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor metabolism, Cystadenocarcinoma, Serous pathology, Ovarian Neoplasms pathology, Peritoneal Neoplasms secondary, Toll-Like Receptors metabolism
- Abstract
Purpose: Ovarian cancer continues to be the most lethal gynecologic malignancy, with a complex tumor microenvironment (TME). We investigated the immunohistochemical (IHC) expression of toll like receptors (TLRs) 4,5,7 and 9 together with CD68 and CD 163 as markers for tumor-associated macrophages (TAM) in relation to clinicopathological data., Methods: Data from 102 patients with serous ovarian cancer treated between 2006 and 2011 was retrospectively reviewed. A TLR IHC score was developed and CD68, CD163 density scores were calculated as the mean number of positive cells from three 0.5 mm2 areas., Results: Advanced-stage disease (FIGO IIIC-IV) was present in 65.7% of cases. A TLR4 score above median was associated with peritoneal carcinomatosis (odds ratio/OR) 3.02, p=0.019) or ascites (OR 2.5, p=0.041). In FIGO stage IIIC-IV patients with a platinum-free interval (PFI) >12 months had, in comparison with patients with PFI ≤12 months, a higher CD68 density score (191.9 ± 95.2 vs. 152.7 ± 69.4, p=0.066) and a lower CD163 density score (106.7 ± 73.3 vs. 154.5 ± 73.9, p=0.011). In early-stage ovarian cancer patients, TLR9 positivity was associated with a higher overall survival than in patients with absent expression (110.2 vs. 22 months, p<0.001), while advanced-stage patients with TLR7 positivity had a lower overall survival than patients with negative TLR7 (38.3 vs. 66.2 months, p=0.01)., Conclusions: Our data shows that TLRs and TAM are important prognostic markers and future studies are needed to better comprehend the immune response in ovarian cancer.
- Published
- 2018
15. The prognostic role of Skp2 and the tumor suppressor protein p27 in colorectal cancer.
- Author
-
Vasile Bochis O, Achimas-Cadariu P, Vlad C, Fetica B, Corneliu Leucuta D, Ioan Busuioc C, and Irimie A
- Subjects
- Colorectal Neoplasms mortality, Colorectal Neoplasms pathology, Cyclin-Dependent Kinase Inhibitor p27 metabolism, Female, Humans, Male, Prognosis, Retrospective Studies, S-Phase Kinase-Associated Proteins metabolism, Survival Analysis, Colorectal Neoplasms genetics, Cyclin-Dependent Kinase Inhibitor p27 genetics, Immunohistochemistry methods, S-Phase Kinase-Associated Proteins genetics
- Abstract
Purpose: This study aimed at exploring the role of Skp2, p27 and Cks1 expression as prognostic factors for colorectal cancer (CRC) patients, and to identify a correlation between their expression and the cell proliferation marker Ki67., Methods: We conducted a retrospective study on 130 patients with CRC treated with surgery and adjuvant treatment at the Oncology Institute Cluj-Napoca between 2006- 2010. The Skp2, p27, Cks1 and Ki67 immunoexpression was grouped from 1 to 4, according to percents of tumor cells with nuclear reactivity. Their correlation with overall survival (OS), recurrence free survival (RFS) and with the classical histopathological prognostic factors were analyzed. All patients had 5-year follow-up., Results: The majority of patients had locally advanced TNM stages II and III. More than a half of the tumors had low immunoexpression of Skp2 and Cks1, and high and moderate p27 and Ki67 expression. Skp2 overexpression negatively influenced the p27 (p=0.002). Both OS and RFS were significantly higher in patients with moderate and high expression of p27 (p=0.005). Skp2 and Cks1 overexpression negatively influenced OS and RFS. Skp2 overexpression positively correlated with TNM stage (p<0.001), node capsular invasion (p=0.002) and lymphovascular invasion (p=0.042). Ki67 expression did not correlate with Skp2 (p=0.88), Cks1 (p=0.67) and p27 (p=0.40), neither with OS (p=0.841) and RFS (p=0.84)., Conclusions: The most important prognostic factor was the Skp2 overexpression. It was the only protein we studied that correlated with the other well-known prognostic factors in CRC. The expression of Ki67 did not bring any novel prognostic information regarding CRC.
- Published
- 2017
16. Preliminary study on the role of secondary surgery in ovarian cancer patients. Experience of a tertiary institution.
- Author
-
Vlad C, Kubelac P, Alexandru I, and Achimas-Cadariu P
- Subjects
- Cytoreduction Surgical Procedures, Female, Humans, Ovarian Neoplasms surgery
- Published
- 2017
17. Tumor infiltrating lymphocytes as a prognostic factor in malignant melanoma. Review of the literature.
- Author
-
Gata VA, Lisencu CI, Vlad CI, Piciu D, Irimie A, and Achimas-Cadariu P
- Subjects
- Forkhead Transcription Factors physiology, Humans, Lymphatic Metastasis, Melanoma immunology, Melanoma mortality, Prognosis, T-Lymphocytes, Regulatory physiology, Lymphocytes, Tumor-Infiltrating physiology, Melanoma pathology
- Abstract
Malignant melanoma represents the major cause of mortality among skin cancers, with increasing incidence and mortality rates worldwide. Despite the numerous public health campaigns and the efforts undertaken in the last decade regarding the establishment of a rapid diagnostic and an efficient treatment for these patients, the long-term prognosis has not been significantly improved. Thus, numerous studies were conducted in order to establish a more accurate prognosis, tumor infiltrating lymphocytes (TILs) being considered in many studies as independent prognostic factors of lymph node metastasis and overall survival in patients with melanoma. Moreover, immunotherapy has been intensively studied and evolved in recent times, and represents a promising treatment option for patients with advanced stage (metastatic) malignant melanoma. In this review article, we provided a literature overview on the histological classification, the history and the essential role of TILs, as well as the implications of regulatory T (Treg) cells and FOX P3 transcription factor in malignant melanoma.
- Published
- 2017
18. Platinum derivatives: a multidisciplinary approach.
- Author
-
Gheorghe-Cetean S, Cainap C, Oprean L, Hangan A, Virag P, Fischer-Fodor E, Gherman A, Cainap S, Constantin AM, Laszlo I, Vlad C, and Oprean R
- Subjects
- Carboplatin adverse effects, Carboplatin chemistry, Carboplatin pharmacology, Cisplatin adverse effects, Cisplatin chemistry, Cisplatin pharmacology, Drug Resistance, Neoplasm, Humans, Oxaliplatin adverse effects, Oxaliplatin chemistry, Oxaliplatin pharmacology, Tumor Suppressor Protein p53 physiology, Antineoplastic Agents pharmacology, Organoplatinum Compounds pharmacology
- Abstract
Cancer is one of the most difficult diseases to be treated. The particularities regarding the tumors' occurrence mechanism, their evolution under chemotherapy, disease-free interval, but also the increasing number of patients make cancer an intensively studied health domain. Although introduced in therapy since the early 80s, platinum derivatives play an essential role in anticancer therapy. Their use in therapy resulted in improving the patient quality of life and prolonging disease-free interval, which makes them still a benchmark for other anticancer compounds. However, adverse reactions and allergic reactions are a major impediment in therapy with platinum derivatives. This paper summarizes data about platinum derivatives through a multidisciplinary approach, starting from a chemical point of view and on to their mechanism of action, mechanism of cellular resistance, predictive factors for the outcome of chemotherapy such as micro RNAs (miRNAs), tumor suppressor protein p53, and the excision repair cross-complementing 1 protein (ERCC1).
- Published
- 2017
19. Expression of Nestin and CD133 in serous ovarian carcinoma.
- Author
-
Onisim A, Iancu M, Vlad C, Kubelac P, Fetica B, Fulop A, Achimas-Cadariu A, and Achimas-Cadariu P
- Subjects
- Adult, Aged, Antigens, CD34 analysis, Carcinoma pathology, Carcinoma therapy, Chi-Square Distribution, Endothelial Cells pathology, Female, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Middle Aged, Multivariate Analysis, Neoplasms, Cystic, Mucinous, and Serous blood supply, Neoplasms, Cystic, Mucinous, and Serous pathology, Neoplasms, Cystic, Mucinous, and Serous therapy, Neovascularization, Pathologic, Odds Ratio, Ovarian Neoplasms blood supply, Ovarian Neoplasms pathology, Ovarian Neoplasms therapy, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Risk Factors, Tissue Array Analysis, AC133 Antigen analysis, Biomarkers, Tumor analysis, Carcinoma chemistry, Endothelial Cells chemistry, Neoplasms, Cystic, Mucinous, and Serous chemistry, Nestin analysis, Ovarian Neoplasms chemistry
- Abstract
Pupose: Nestin and CD133 are regarded as putative markers of cancer stem cells (CSCs) and related to poor prognosis in various cancer sites. Since few studies have focused on their role in ovarian cancer, we aimed to investigate their predictive value and association with neoangiogenesis., Methods: Immunohistochemical analysis for nestin and CD133 was performed on 85 serous ovarian carcinoma tumor samples using tissue microarray technique. Nestin immunoreactivity was detected in both tumor and endothelial cells, whilst CD133 was only identified in tumor cells. CD34 endothelial expression was used to assess intratumor microvessel density (MVD)., Results: Of the tissue samples 49.4% were nestin-positive and 24.7% were positive for CD133. In both univariate and multivariate analysis nestin or CD133 expressions in tumor cells were not significantly associated with clinicopathological parameters (age, serum CA125, peritoneal carcinomatosis, malignant ascites, tumor grade). However, in multivariate analysis nestin expression in tumor cells proved to be an independent prognostic factor, associated with poorer survival and time to progression (p=0.025 and p=0.05, respectively). This has not been achieved for CD133. Furthermore, a significant concordance between nestin endothelial expression (nestin-determined MVD) and CD34-determined MVD was achieved., Conclusion: In addition to the well-known clinicopathological characteristics, tumor expression of nestin might be a valuable prognostic factor for survival in patients with advanced ovarian cancer. With regard to its endothelial expression, nestin might be as reliable as CD34 for quantifying tumor angiogenesis. Further investigation is justified in order to better clarify the role of these biomarkers.
- Published
- 2016
20. The role of primary debulking in advanced ovarian cancer patients.
- Author
-
Vlad C, Kubelac P, Alexandru I, and Achimas-Cadariu P
- Subjects
- Carcinoma, Ovarian Epithelial, Female, Humans, Margins of Excision, Neoplasm Staging, Neoplasms, Glandular and Epithelial mortality, Neoplasms, Glandular and Epithelial pathology, Ovarian Neoplasms mortality, Ovarian Neoplasms pathology, Retrospective Studies, Risk Factors, Romania, Survival Analysis, Time Factors, Treatment Outcome, Cytoreduction Surgical Procedures adverse effects, Cytoreduction Surgical Procedures mortality, Gynecologic Surgical Procedures adverse effects, Neoplasms, Glandular and Epithelial surgery, Ovarian Neoplasms surgery
- Published
- 2016
21. Expression of CDCP1 and ADAM12 in the ovarian cancer microenvironment.
- Author
-
Vlad C, Kubelac P, Onisim A, Fetica B, Fulop A, Irimie A, and Achimas-Cadariu P
- Subjects
- Adult, Aged, Antigens, Neoplasm, Biomarkers, Tumor genetics, Endothelial Cells pathology, Female, Humans, Microvessels pathology, Middle Aged, Neovascularization, Pathologic genetics, Neovascularization, Pathologic pathology, Ovarian Neoplasms pathology, Prognosis, Retrospective Studies, ADAM12 Protein genetics, Antigens, CD genetics, Cell Adhesion Molecules genetics, Neoplasm Proteins genetics, Ovarian Neoplasms genetics, Tumor Microenvironment genetics
- Abstract
Purpose: The tumor microenvironment in ovarian cancer (OC) seems to play an important role, and besides tumor cells, biomarkers can derive from endothelial cells. We investigated CDCP1 and ADAM12 expression in relation with other clinical and pathological characteristics in OC patients., Methods: We retrospectively evaluated patient files between 2006-2011. A histochemical score was developed to evaluate tumor staining, the microvessel density (MVD), and stromal expression patterns for both ADAM12 and CDCP1. A CD34 antibody was used to assess tumor MVD., Results: 102 patients were selected and 83% had FIGO stage III/IV. A high CDCP1 tumor score correlated significantly with a shorter overall survival (OS) (p<0.01). Cases with positive CDCP1 had an elevated CD34 MVD (p<0.01). An absent/low ADAM12 tumor score correlated with significantly improved OS (p<0.01). Mean CD34 MVD was higher in cases with positive ADAM12 MVD (p=0.012)., Conclusions: Our results indicate that both tumor markers are negative prognostic factors for overall survival and additional studies are required to validate their future potential.
- Published
- 2016
22. The role of CDCP1 (CUB domain-containing protein 1) and ADAM12 (a disintegrin and metalloproteinase 12) in ovarian cancer.
- Author
-
Vlad C, Kubelac P, Onisim A, Irimie A, and Achimas-Cadariu P
- Subjects
- ADAM12 Protein, Animals, Antigens, Neoplasm, Disease Progression, Endothelial Cells enzymology, Female, Humans, Neoplasm Invasiveness, Ovarian Neoplasms pathology, Signal Transduction, Tumor Microenvironment, ADAM Proteins metabolism, Antigens, CD metabolism, Biomarkers, Tumor metabolism, Cell Adhesion Molecules metabolism, Membrane Proteins metabolism, Neoplasm Proteins metabolism, Ovarian Neoplasms blood supply, Ovarian Neoplasms enzymology
- Abstract
Ovarian cancer (OC) is the second most common gynecological cancer and the deadliest in industrialized countries, with poor outcomes that indicate an urgent need to provide a greater insight into the molecular mechanisms underlying OC. Insights into the complex tumor microenviroment show that besides tumor islets, OC biomarkers can derive from newly formed blood vessels that have endothelial cells with a different molecular signature in comparison with their normal counterparts. In this view, recent research has been able to highlight promising candidates such as CDCP1 and ADAM12. Our present review summarises their implications in cancer progression with a focus on OC.
- Published
- 2015
23. Current insights into the association of Nestin with tumor angiogenesis.
- Author
-
Onisim A, Achimas-Cadariu A, Vlad C, Kubelac P, and Achimas-Cadariu P
- Subjects
- Angiogenesis Inhibitors therapeutic use, Animals, Endothelial Cells metabolism, Endothelial Cells pathology, Humans, Molecular Targeted Therapy, Neoplasms drug therapy, Neoplasms pathology, Neoplastic Stem Cells drug effects, Neoplastic Stem Cells pathology, Signal Transduction, Neoplasms blood supply, Neoplasms metabolism, Neoplastic Stem Cells metabolism, Neovascularization, Pathologic, Nestin metabolism
- Abstract
Tumor angiogenesis is regarded as a hallmark of cancer and provides an important target for therapy. Nestin is an intermediate filament protein (IF) originally recognized as a neural stem cell marker. Development and progression of cancer requires sustained angiogenesis, dependent on the proliferation and migration of endothelial cells which seem to be better portrayed by nestin expression in various malignancies such as central nervous system, gastro-intestinal cancers, malignant melanoma, lung, prostate or breast cancer. The purpose of the present review was to emphasize the insights into nestin expression in relation to tumor angiogenesis in different types of cancer. Current evidence suggests that nestin positivity in tumor cells reflects stem-like properties of those cells. Whether or not expressed in both tumor and endothelial cells, nestin overexpression might reflect the extent of angiogenesis and function as a molecular anti-angiogenic target for cancer.
- Published
- 2015
24. The prognostic value of FOXP3+ T regulatory cells in colorectal cancer.
- Author
-
Vlad C, Kubelac P, Fetica B, Vlad D, Irimie A, and Achimas-Cadariu P
- Subjects
- Adult, Aged, CD3 Complex analysis, Colorectal Neoplasms mortality, Colorectal Neoplasms pathology, Colorectal Neoplasms therapy, Female, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Young Adult, Biomarkers, Tumor analysis, Colorectal Neoplasms immunology, Forkhead Transcription Factors analysis, T-Lymphocytes, Regulatory immunology
- Abstract
Purpose: The evaluation of CD3(+) T-cell density is believed to have a higher prognostic value than the conventionally used TMN stage in colorectal cancer (CRC), but the role of regulatory T lymphocytes (Treg) is still debated. Our study determined the prognostic value of forkhead box P3 nuclear transcription factor (FOXP3) positive Treg and CD3(+) T-cells in the invasive margin of CRC compared with other known prognostic factors., Methods: The prognostic factors analysed in 42 patients with CRC stage II (N=13) and III (N=29), were age, tumor location, TNM stage, histological grade, vascular, lymphatic and perineural invasion. CD3(+) T-cells and FOXP3(+) Treg density was evaluated by immunohistochemistry., Results: The median CD3(+) T-cells and FOXP3(+) Treg density was 438.93/mm(2) and 162.25/mm(2), respectively. Patients with high FOXP3(+) Treg density showed improved 5-year survival rate of 89.41%, compared with 64.6% of those with low density (p=0.024)., Conclusions: Increased CD3(+) T-cells and FOXP3(+) Treg density is associated with improved survival, but only the latter proved to be an independent prognostic factor. FOXP3(+) Treg infiltrate may play an important prognostic role, which, in combination with other predictive factors, could lead to the development of specific treatment regimens.
- Published
- 2015
25. Evaluation of clinical, morphopathological and therapeutic prognostic factors in rectal cancer. Experience of a tertiary oncology center.
- Author
-
Vlad C, Kubelac P, Vlad D, Irimie A, and Achimas Cadariu P
- Subjects
- Age Factors, Aged, Female, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis, Male, Middle Aged, Multivariate Analysis, Neoplasm Invasiveness, Neoplasm Staging, Proportional Hazards Models, Rectal Neoplasms mortality, Retrospective Studies, Risk Factors, Romania, Time Factors, Treatment Outcome, Rectal Neoplasms pathology, Rectal Neoplasms therapy, Tertiary Care Centers
- Abstract
Purpose: Morphopathological factors continue to be the most important prognostic factors in colorectal cancer, but there is evidence regarding the prognostic value of some factors that are not yet used in current clinical practice. The purpose of the present study was to evaluate the most important clinical, morphopathological and therapeutic prognostic factors in rectal cancer., Methods: This study retrospectively analyzed 317 patients diagnosed and treated at the Ion Chiricuta Institute of Oncology between 2000-2008. The prognostic value of 13 variables was analyzed and correlations between them were established. Nine variables were included in a multivariate analysis model., Results: The 5-year overall survival (OS) was 55.6%, significantly higher for patients with TNM stage I disease 7l.7%), compared to stage II (71.4%), stage III (45.4%) and stage IV (12.5%; p<0.001). In multivariate analysis, the independent prognostic factors were tumor stage, age, lymph node invasion, venous, lymphatic and perineural invasion., Conclusions: In addition to the TNM stage and lymph node invasion, age, venous, lymphatic and perineural invasion were also proved to have prognostic significance in rectal cancer. Further studies are required for the validation of prognostic assessment models in patients diagnosed with rectal cancer.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.